Background
SEER population-based analysis of 4,229 patients with stage IV melanoma (1988-2006), comparing outcomes of patients who underwent metastasectomy (33.6%) with those who did not.
Interventions and follow up
Cohort 1: Metastasectomy
Cohort 2: No metastasectomy (observation)
Design: retrospective SEER cohort analyzed by metastasectomy status
Primary endpoint: median survival and overall survival
Median follow-up: NR
Cohort 2: No metastasectomy (observation)
Design: retrospective SEER cohort analyzed by metastasectomy status
Primary endpoint: median survival and overall survival
Median follow-up: NR
Results
5-yr OS: 20% vs 9% (metastasectomy vs observation); HR 0.59, 95%CI 0.55-0.63
Median OS (all patients): 12mo vs 5mo, P<.001
Median OS (M1a disease): 14mo vs 6mo, P<.001
Median OS (M1b disease): 10mo vs 4mo, P<.001
Median OS (all patients): 12mo vs 5mo, P<.001
Median OS (M1a disease): 14mo vs 6mo, P<.001
Median OS (M1b disease): 10mo vs 4mo, P<.001
Adverse events
Surgical morbidity: NR
Note: adverse events and operative complications were not captured in this SEER-based observational analysis
Note: adverse events and operative complications were not captured in this SEER-based observational analysis
Conclusions
Metastasectomy was associated with longer survival across M1a and M1b subgroups, supporting consideration of surgical resection in selected stage IV melanoma patients on a case-by-case basis.
Key Limitations
Retrospective, non-randomized design with strong selection bias (healthier, lower-burden patients undergo surgery); SEER lacks systemic-therapy and performance-status data; pre-dates modern immunotherapy and targeted therapy.
Clinical Context
Hypothesis-generating evidence supporting selective metastasectomy in oligometastatic melanoma. In the modern era, surgery is integrated with systemic immunotherapy/targeted therapy. ESMO endorses surgery for selected oligometastatic disease as part of multimodal management.
References